ASCO 2020 Virtual Annual Meeting Conference Review - focus on Melanoma, reviewed by Dr. Rachel Rober

In this review:

RFS for pembrolizumab after complete resection of high-risk stage III melanoma
Five-year analysis of COMBI-AD
Twenty-four months RFS and updated toxicity data from OpACIN-neo
Personalised response-driven surgery and adjuvant therapy after ipilimumab and nivolumab
The need for >2 doses of nivolumab + ipilimumab
Ipilimumab alone or in combination with anti-PD-1 in patients resistant to PD-1 monotherapy
Low-dose ipilimumab with pembrolizumab following progression on anti-PD-1
Long-term data from KEYNOTE-006
Long-term follow-up of lifileucel in patients who progressed on multiple prior therapies
Concurrent intrathecal and intravenous nivolumab for leptomeningeal disease

Please login below to download this issue (PDF)